Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives

被引：65

作者：

Irving, Peter M. ^{[1
,2
,4
]}

Gecse, Krisztina B. ^{[3
]}

机构：

[1] Guys & St Thomas Hosp, Dept Gastroenterol, IBD Unit, London, England

[2] Kings Coll London, Sch Immunol & Microbial Sci, London, England

[3] Amsterdam UMC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

[4] St Thomas Hosp, Dept Gastroenterol, 1st Floor,Coll House,South Wing,Westminster Bridge, London SE1 7EH, England

来源：

GASTROENTEROLOGY | 2022年 / 162卷 / 05期

基金：

英国医学研究理事会;

关键词：

Crohn's Disease; Inflammatory Bowel Diseases; Therapeutic Drug Monitoring; Ulcerative Colitis; INFLAMMATORY-BOWEL-DISEASE; INDUCTION INFLIXIMAB LEVELS; ULCERATIVE-COLITIS; COMBINATION THERAPY; TROUGH LEVELS; MAINTENANCE THERAPY; CLINICAL-RESPONSE; CROHNS-DISEASE; AZATHIOPRINE; ASSOCIATION;

D O I：

10.1053/j.gastro.2022.02.014

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end points. Optimal drug concentrations in inflammatory bowel disease vary according to treatment target, disease phenotype, inflammatory burden, and timing of sampling during the treatment cycle. This review provides an update on TDM with biologic and oral small molecules, evaluates the role of reactive vs proactive TDM, and identifies the gaps in current evidence. In the future, adaptations to how we use TDM may contribute further to the goal of personalized treatment in patients with IBD.

引用

页码：1512 / 1524

页数：13

共 100 条

[1] Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis [J].

Adedokun, Omoniyi J. ;

Xu, Zhenhua ;

Marano, Colleen ;

O'Brien, Chris ;

Szapary, Philippe ;

Zhang, Hongyan ;

Johanns, Jewel ;

Leong, Rupert W. ;

Hisamatsu, Tadakazu ;

Van Assche, Gert ;

Danese, Silvio ;

Abreu, Maria T. ;

Sands, Bruce E. ;

Sandborn, William J. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (10) :2244-+

[2] Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease [J].

Adedokun, Omoniyi J. ;

Xu, Zhenhua ;

Gasink, Christopher ;

Jacobstein, Douglas ;

Szapary, Philippe ;

Johanns, Jewel ;

Gao, Long-Long ;

Davis, Hugh M. ;

Hanauer, Stephen B. ;

Feagan, Brian G. ;

Ghosh, Subrata ;

Sandborn, William J. .

GASTROENTEROLOGY, 2018, 154 (06) :1660-1671

[3]

Adedokun OJ, 2017, J CROHNS COLITIS, V11, P35, DOI 10.1093/ecco-jcc/jjw133

[4]

Aguiar Zdovc J, PHARMACEUTICS, V13, P1587

[5] Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring [J].

Assa, Amit ;

Matar, Manar ;

Turner, Dan ;

Broide, Efrat ;

Weiss, Batia ;

Ledder, Oren ;

Guz-Mark, Anat ;

Rinawi, Firas ;

Cohen, Shlomi ;

Topf-Olivestone, Chani ;

Shaoul, Ron ;

Yerushalmi, Baruch ;

Shamir, Raanan .

GASTROENTEROLOGY, 2019, 157 (04) :985-+

[6] Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease [J].

Ben-Horin, Shomron ;

Waterman, Matti ;

Kopylov, Uri ;

Yavzori, Miri ;

Picard, Orit ;

Fudim, Ella ;

Awadie, Halim ;

Weiss, Batia ;

Chowers, Yehuda .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (04) :444-447

[7] Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study [J].

Berends, Sophie E. ;

Strik, Anne S. ;

Jansen, Jeroen M. ;

de Boer, Nanne K. ;

van Egmond, Pleun S. ;

Brandse, Johannan F. ;

Mathot, Ron A. ;

D'Haens, Geert R. ;

Lowenberg, Mark .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2019, 54 (06) :700-706

[8] Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation [J].

Berends, Sophie E. ;

D'Haens, Geert R. A. M. ;

Schaap, Tiny ;

de Vries, Annick ;

Rispens, Theo ;

Bloem, Karien ;

Mathot, Ron A. A. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) :1544-1551

[9] Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial [J].

Bossuyt, Peter ;

Pouillon, Lieven ;

Claeys, Sophie ;

D'Haens, Soetkin ;

Hoefkens, Eveline ;

Strubbe, Beatrijs ;

Marichal, Denis ;

Peeters, Harald .

JOURNAL OF CROHNS & COLITIS, 2022, 16 (02) :199-206

[10] Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis [J].

Brandse, Johannan F. ;

Mathot, Ron A. ;

van der Kleij, Desiree ;

Rispens, Theo ;

Ashruf, Yael ;

Jansen, Jeroen M. ;

Rietdijk, Svend ;

Lowenberg, Mark ;

Ponsioen, Cyriel Y. ;

Singh, Sharat ;

van den Brink, Gijs R. ;

D'Haens, Geert R. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (02) :251-+

← 1 2 3 4 5 6 7 8 9 10 →